Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases

42

NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that the Company has converted its option and entered into an exclusive global license agreement with UPenn. http://www.businesswire.com/news/home/20190411005845/en/Ophthotech-Obtains-Exclusive-Global-License-AAV-Gene/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==